Icon Group Executive and Leadership Team

November, 2026

Leadership Overview

Icon Group has 10 executives leading key functions including oncology strategy, clinical operations, financial management, and digital infrastructure.

Focused on delivering world-class cancer care, Icon Group advances patient recovery through integrated oncology, radiation therapy, and pharmacy services across the Australian healthcare landscape.

Leadership Roles at Icon Group

  • Chief Executive Officer - Chelsea Ren
  • Chief Executive Officer, Cancer Services & Zealand (Australia) - Paul Fenton
  • Group Chief Executive Officer & Group Executive Director, Icon Oncology Board - Mark Middleton
  • Global Chief Executive Officer, Commercial & Services - Tracey Fyvie
  • Chief Financial Officer - Conal Henderson
  • Multi-Sector Sales & Operations Business Development Leadership Executive & President - Jeremy Kammerer
  • Chief Information Officer - Mark Macdonald
  • Chief Medical Officer - Ian Irving
  • Deputy Chief Medical Officer - Matthew Foote
  • Managing Director - Wayne Neary
  • Chelsea Ren - Chief Executive Officer

    Chelsea Ren, the Chief Executive Officer at Icon Group, directs the overarching strategic vision for cancer care delivery across the Australian network. Ren manages the alignment of oncology, radiation, and pharmacy services to ensure consistent patient outcomes. By overseeing the integration of clinical workflows, the Chief Executive Officer optimizes operational efficiency within the hospital and clinic infrastructure. This leadership role involves constant collaboration with the board to refine the long-term growth trajectory of the organization. Chelsea Ren drives the expansion of specialized treatment facilities, ensuring that high-quality care remains accessible to patients throughout the region. Through rigorous oversight of service delivery models, the Chief Executive Officer maintains the standard of excellence required for complex cancer treatments. Ren secures the future of the organization by fostering innovation in clinical practice and operational management, ultimately strengthening the market position of the company within the competitive healthcare sector.

    Paul Fenton - Chief Executive Officer, Cancer Services & Zealand (Australia)

    Paul Fenton, the Chief Executive Officer, Cancer Services & Zealand (Australia) at Icon Group, architects the operational framework for cancer services across the Australian and regional markets. Fenton manages the deployment of radiation oncology and chemotherapy compounding resources to maximize patient recovery rates. Overseeing the clinical service lines, the Chief Executive Officer, Cancer Services & Zealand (Australia) ensures that all facilities adhere to strict safety and quality protocols. This leadership role involves coordinating with regional medical teams to standardize treatment pathways and improve service accessibility. Paul Fenton drives the implementation of advanced oncology technologies, directly impacting the efficacy of patient care programs. By monitoring performance metrics across the service network, the Chief Executive Officer, Cancer Services & Zealand (Australia) identifies opportunities for operational scaling. Fenton secures the operational integrity of the cancer care division, ensuring that the organization meets the evolving needs of patients throughout the diverse geographic footprint.

    Mark Middleton - Group Chief Executive Officer & Group Executive Director, Icon Oncology Board

    Mark Middleton, the Group Chief Executive Officer & Group Executive Director, Icon Oncology Board at Icon Group, governs the strategic direction of the entire oncology portfolio. Middleton manages the relationship between the executive leadership team and the board to ensure alignment with the core mission of providing comprehensive cancer care. Overseeing the group-wide oncology strategy, the Group Chief Executive Officer & Group Executive Director, Icon Oncology Board directs the expansion of radiation and pharmacy services. This leadership role involves high-level decision-making regarding capital investments and the acquisition of new clinical assets. Mark Middleton drives the organizational culture toward excellence in patient-centered care, ensuring that all departments operate with clinical precision. By evaluating market trends and healthcare policy, the Group Chief Executive Officer & Group Executive Director, Icon Oncology Board positions the company as a leader in the Australian oncology sector. Middleton secures long-term sustainability through disciplined financial and clinical governance.

    Tracey Fyvie - Global Chief Executive Officer, Commercial & Services

    Tracey Fyvie, the Global Chief Executive Officer, Commercial & Services at Icon Group, directs the commercial strategy and service delivery models that support the company's oncology operations. Fyvie manages the business development initiatives and service partnerships that expand the reach of cancer care across the Australian market. Overseeing the commercial performance of the pharmacy and compounding divisions, the Global Chief Executive Officer, Commercial & Services ensures that operational revenue supports the broader clinical mission. This leadership role involves negotiating strategic alliances and optimizing the supply chain for essential oncology medications. Tracey Fyvie drives the growth of service offerings by identifying new market opportunities and enhancing existing patient care programs. By aligning commercial objectives with clinical requirements, the Global Chief Executive Officer, Commercial & Services maintains the financial health of the organization. Fyvie secures competitive advantages through innovative service delivery and efficient management of commercial resources.

    Conal Henderson - Chief Financial Officer

    Conal Henderson, the Chief Financial Officer at Icon Group, directs the financial strategy and fiscal health of the organization. Henderson manages the capital allocation for oncology infrastructure, including the procurement of advanced radiation equipment and pharmacy resources. Overseeing the financial reporting and budgeting processes, the Chief Financial Officer ensures that the company maintains the resources necessary to support its cancer care mission. This leadership role involves analyzing market data to inform investment decisions and long-term growth strategies. Conal Henderson drives the optimization of financial performance across all clinical divisions, ensuring that revenue streams remain robust. By monitoring economic trends and healthcare funding models, the Chief Financial Officer mitigates financial risk and supports the expansion of services. Henderson secures the fiscal foundation of the company, enabling the continued delivery of high-quality cancer care to patients throughout the Australian region.

    Jeremy Kammerer - Multi-Sector Sales & Operations Business Development Leadership Executive & President

    Jeremy Kammerer, the Multi-Sector Sales & Operations Business Development Leadership Executive & President at Icon Group, directs the business development strategy for new market entry and service expansion. Kammerer manages the sales operations that connect the company's oncology services with broader healthcare networks. Overseeing the growth of the business development pipeline, the Multi-Sector Sales & Operations Business Development Leadership Executive & President identifies opportunities to integrate radiation and pharmacy services into new regions. This leadership role involves building strategic relationships with healthcare providers to expand the reach of the company's cancer care model. Jeremy Kammerer drives the execution of sales initiatives that increase patient volume and service utilization. By aligning business development efforts with operational capabilities, the Multi-Sector Sales & Operations Business Development Leadership Executive & President ensures sustainable growth. Kammerer secures the market presence of the organization through proactive engagement and strategic partnership development.

    Mark Macdonald - Chief Information Officer

    Mark Macdonald, the Chief Information Officer at Icon Group, architects the digital infrastructure that supports the company's oncology and pharmacy operations. Macdonald manages the implementation of health information systems that track patient data and treatment progress across the Australian network. Overseeing the cybersecurity and data integrity protocols, the Chief Information Officer ensures that sensitive patient information remains protected while remaining accessible to clinical teams. This leadership role involves integrating new technologies into the existing clinical workflow to improve diagnostic accuracy and treatment efficiency. Mark Macdonald drives the digital transformation of the organization, enabling better coordination between radiation oncology and chemotherapy services. By leveraging data analytics, the Chief Information Officer provides insights that inform clinical decision-making and operational improvements. Macdonald secures the technological backbone of the company, ensuring that digital tools enhance the overall quality of cancer care delivery.
    Mark Macdonald

    Ian Irving - Chief Medical Officer

    Ian Irving, the Chief Medical Officer at Icon Group, directs the clinical standards and medical governance for the entire organization. Irving manages the recruitment and professional development of oncology specialists to ensure that patients receive the highest level of care. Overseeing the clinical protocols for radiation therapy and chemotherapy, the Chief Medical Officer ensures that all treatments align with current medical research and safety guidelines. This leadership role involves collaborating with the board to establish clinical policies that define the company's approach to cancer care. Ian Irving drives the adoption of evidence-based practices across all clinics, directly impacting patient recovery outcomes. By monitoring clinical performance and quality assurance metrics, the Chief Medical Officer maintains the reputation of the company as a leader in oncology. Irving secures the clinical integrity of the organization, ensuring that medical excellence remains the cornerstone of all patient interactions.

    Matthew Foote - Deputy Chief Medical Officer

    Matthew Foote, the Deputy Chief Medical Officer at Icon Group, supports the clinical leadership in maintaining high standards of oncology care. Foote manages the implementation of specialized treatment protocols within the radiation oncology department to ensure consistency across all facilities. Overseeing the clinical audit processes, the Deputy Chief Medical Officer identifies areas for improvement in patient care delivery. This leadership role involves working closely with the Chief Medical Officer to refine medical policies and integrate new research into daily practice. Matthew Foote drives the training and mentorship of clinical staff, ensuring that the team remains proficient in the latest cancer treatment techniques. By focusing on the operational details of clinical governance, the Deputy Chief Medical Officer enhances the overall quality of the patient experience. Foote secures the clinical standards of the organization, ensuring that every treatment plan reflects the latest advancements in oncology and patient safety.

    Wayne Neary - Managing Director

    Wayne Neary, the Managing Director at Icon Group, oversees the day-to-day operational execution of the company's cancer care facilities. Neary manages the administrative and clinical staff to ensure that radiation oncology and chemotherapy services function seamlessly. By directing the operational workflows within the clinics, the Managing Director ensures that patient care remains the primary focus of all activities. This leadership role involves coordinating with regional managers to maintain high standards of service delivery across the Australian network. Wayne Neary drives the implementation of operational improvements that increase efficiency and reduce wait times for patients. Through the oversight of facility management and resource allocation, the Managing Director supports the broader strategic goals of the organization. Neary secures the operational stability of the company by fostering a culture of accountability and clinical excellence, ensuring that every facility meets the rigorous demands of modern oncology practice.

    Explore Leadership Teams in Hospitals & Physicians Clinics

    Frequently Asked Questions Regarding Icon Group Top Executives and Leadership Team

    Who leads Icon Group?
    Icon Group is led by Chelsea Ren (Chief Executive Officer), along with executives such as Paul Fenton (Chief Executive Officer, Cancer Services & Zealand (Australia)) and Mark Middleton (Group Chief Executive Officer & Group Executive Director, Icon Oncology Board).
    Who is part of Icon Group’s executive team?
    The executive team of Icon Group includes leaders such as Chelsea Ren (Chief Executive Officer), Paul Fenton (Chief Executive Officer, Cancer Services & Zealand (Australia)), Mark Middleton (Group Chief Executive Officer & Group Executive Director, Icon Oncology Board) and other senior executives.
    How many executives does Icon Group have?
    Icon Group has 10 executives leading key business areas.
    What roles are included in Icon Group’s leadership team?
    The leadership team of Icon Group includes roles such as Chief Executive Officer, Chief Executive Officer, Cancer Services & Zealand (Australia), Group Chief Executive Officer & Group Executive Director, Icon Oncology Board, Global Chief Executive Officer, Commercial & Services, Chief Financial Officer.